Cognition Therapeutics, Inc. (CGTX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Cognition Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying therapies for age-related degenerative diseases of the central nervous system (CNS) and retina. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of May 5, 2026, there were 89,498,015 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue / Grant Income | $3,979 | $5,086 |
| Net Loss | $(4,570) | $(8,480) |
| Net Loss Per Share (Basic & Diluted) | $(0.05) | $(0.14) |
| Operating Expenses | $8,817 | $13,775 |
| Cash and Cash Equivalents (End of Period) | $31,130 | $16,428 |
| Net Cash Used in Operating Activities | $(5,542) | $(9,877) |
| Accumulated Deficit | $(203,217) | $(183,640) |
Note: The company has no product revenue; income is derived primarily from government grants (NIA/NIH).
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by $3.9 million (46%) compared to Q1 2025, driven primarily by a $4.7 million reduction in operating expenses.
- Expense Reduction: Research and Development (R&D) expenses dropped $4.7 million to $6.1 million. This was due to decreased Phase 2 trial activities with contract research organizations (CROs) and reduced personnel costs. General and Administrative (G&A) expenses decreased by $0.3 million.
- Grant Income Decline: Grant income decreased by $1.1 million to $4.0 million, correlating with lower eligible reimbursable costs incurred during the period.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $16.4 million in Q1 2025 to $31.1 million in Q1 2026, bolstered by a registered direct offering in August 2025 that raised approximately $27.9 million in net proceeds.
Outlook, Guidance, and Risks
- Clinical Pipeline Status:
- Alzheimer's Disease (AD): Enrollment concluded in December 2025 for the Phase 2 START study (545 patients). Topline results are expected after 18 months of treatment. The company plans a Phase 3 program for AD patients with lower plasma p-tau217 levels, following FDA concurrence in July 2025.
- Dementia with Lewy Bodies (DLB): The Phase 2 SHIMMER study met its primary endpoint. An expanded access program (EAP) is ongoing. The company plans to meet with the FDA in Q2 2026 to discuss a DLB psychosis program.
- Geographic Atrophy (GA): The Phase 2 MAGNIFY study was voluntarily concluded in January 2025 to conserve resources.
- Liquidity and Capital Resources: Management believes current cash, cash equivalents, and obligated NIA funds (approx. $25.6 million available) are sufficient to fund operations through the second quarter of 2027, assuming no usage of the new ATM facility.
- Financing Facilities:
- The 2022 ATM with B. Riley was terminated in December 2025.
- The Lincoln Park equity line expired in March 2026 without usage in Q1 2026.
- A new 2025 ATM with Jefferies was established in December 2025, allowing up to $75.0 million in sales. No shares were sold under this facility in Q1 2026.
- Risks: The company faces risks related to the ability to raise additional capital, the success of clinical trials, regulatory approvals, and dependence on the lead candidate zervimesine (CT1812). There is no assurance of profitability or future funding availability.
Investor Verification Checklist
- Verify the timeline for topline results from the Phase 2 START study (expected after 18 months of treatment completion).
- Confirm the status of the $25.6 million in obligated NIA funds and the conditions for their release.
- Monitor the outcome of the planned Q2 2026 FDA meeting regarding the DLB psychosis program.
- Track cash burn rate relative to the projected runway through Q2 2027.
- Review the terms and potential dilution impact of the new $75 million ATM facility with Jefferies.